Hubei Jumpcan Pharmaceutical (600566) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was RMB 1.77 billion, down 7.18% year-over-year; net profit attributable to shareholders was RMB 565 million, down 6.58% year-over-year.

• For the first nine months, revenue reached RMB 5.81 billion, a decrease of 11.19% year-over-year; net profit attributable to shareholders was RMB 1.90 billion, down 2.13% year-over-year.

• Cash flow from operating activities for the first nine months was RMB 1.74 billion, down 39.17% year-over-year due to lower sales collections and higher cash outflows for goods and services.

Financial highlights

• Basic and diluted EPS for Q3 was RMB 0.617, down 6.52% year-over-year; for the first nine months, EPS was RMB 2.071, down 2.45%.

• Gross margin remained stable, with operating costs and expenses well managed despite revenue decline.

• Total assets at quarter-end were RMB 18.15 billion, nearly flat from year-end; shareholders' equity increased 5.41% to RMB 14.07 billion.

• Non-recurring gains for the first nine months totaled RMB 204 million, mainly from government subsidies and fair value changes.

Key financial ratios and metrics

• Weighted average ROE for the first nine months was 13.69%, down 2.45 percentage points year-over-year.

• Net profit margin for the first nine months was approximately 32.8%.